Chenkun Ecology
Chenkun Ecology is a mother-fund ecosystem built by Yuanhe Chenkun, leveraging the resource network and scale advantages of its flagship fund to connect government agencies, major capital players, leading industries, fund management firms, and pioneering startups.
Yuanhe Chenkun emphasizes multi-faceted empowerment within its ecosystem, consistently providing partners with a knowledge-sharing platform, a deep-connecting hub for capital and industry players, and a vibrant networking space for entrepreneurs and investors through offline specialized events such as the "Gathering at Shahu – Autumn Forum," the "Kunpeng Hui" industry salon, and dedicated capital-matching sessions.
Review of the Kunpeng Hui Tech-Capital Matchmaking Event: IVD Industry Development and Capital Support
Release date:
2022-06-27
On June 24, 2022, the "Kunpeng Hui" series of ecosystem events—featuring an IVD Industry Development and Capital-Driven Technology-Capital Matching Conference—was held both online and offline, jointly organized by Yuanhe Chencun and Jinhé Capital.
On June 24, 2022, the "Kunpeng Hui" series of ecosystem events—specifically the IVD Industry Development and Capital-Driven Technology-Capital Matching Conference—was held both online and offline, jointly organized by Yuanhe Chencun and Jinhé Capital.
This session features Wang Zhifei, Managing Director and Member of the Investment Committee at Jinhé Capital, and Zhang Ruifeng, General Manager of the Strategic Department at Antu Biotech—both sharing insights from a venture capital perspective on the development of the IVD industry. Additionally, five prominent entrepreneurs will present their innovative projects: Gao Yifeng, CFO of Novogene Bio; He Aimin, Founder of Suzhou Guangjing Bio; Cheng Peng, Founder of Suzhou Caike Bio; Wu Zhicai, Co-founder of Wuhan Abottex; and Zhang Haichuan, Founder of Serena Medical. This event aims to foster robust dialogue and collaboration between cutting-edge innovators and forward-thinking financial investors.
"Investment Opportunities in the In-Vitro Diagnostics Industry"
Wang Zhifei, Jinhe Capital
Currently, the in-vitro diagnostics industry is characterized by a global market dominated by a few oligopolistic players, with both domestic and foreign multinational giants evenly dividing the market share. Looking ahead, the three key drivers of the industry's future growth will be: technological advancements, robust demand, and favorable policy incentives.
From a technological perspective, this is reflected in the expanded clinical application of new technology platforms, the deeper integration of cutting-edge technologies into diagnostic fields, significant advancements in clinical research, and innovative solutions tailored to diverse application scenarios. On the demand side, factors such as population aging and China's comprehensive two-child policy have led to rising numbers of patient visits, overall healthcare spending, and per capita medical costs—driving robust demand for health checkups. Meanwhile, the ongoing impact of the pandemic continues to fuel strong and sustained growth in the in-vitro diagnostics market. Finally, from a policy standpoint, a series of regulations and guidelines aimed at the IVD industry, coupled with initiatives like tiered medical care, are set to foster greater standardization and healthier development within the sector.
When it comes to investment opportunities and strategies, in vitro diagnostics will continue to be a hot spot, offering numerous systemic opportunities. From multiple perspectives—including technology platforms, disease profiles, application scenarios, and the broader industry ecosystem—key investment areas are expected to remain under intense focus: - Opportunities related to existing and emerging technology platforms, particularly their clinical applications; - Clinical application prospects for next-generation sequencing technologies and various types of mass spectrometry platforms; - Ongoing attention to critical nodes across key disease areas such as oncology, infectious diseases, and reproductive health; - Innovative solutions tailored to diverse settings, including central laboratories and hospital labs, smaller labs at mid-sized hospitals, as well as facilities like community clinics, township health centers, and emergency departments in major hospitals—and even clinical departments and home-based care environments; - Investment opportunities spanning the entire value chain, from upstream R&D to downstream distribution and service networks.
"Technological Advancements and Industry Prospects in the IVD Sector"
Zhang Ruifeng, Antu Bio
The technological advancements and industry prospects of the IVD sector can be summarized in four words: low-cost, rapid, precise, and efficient.
Lower costs are being realized in several key areas: First, DRGs and DIP payment reforms have helped curb rising healthcare expenses; second, COVID-19 testing prices have steadily declined; and third, the introduction of fully automated high-throughput laboratory workflows has significantly improved lab space utilization while dramatically reducing operational costs. Testing is now faster, thanks to advancements that have accelerated processes across a range of applications—whether it’s COVID-19 testing, emergency room COVID diagnostics, sequencing-based assays, or traditional chemiluminescence-based tests. Accurate diagnosis is also improving, driven by the identification of more precise biomarkers in pathology, as well as enhanced measurement capabilities for existing marker categories. Looking ahead, investors can capitalize on emerging opportunities arising from major economic trends, such as the booming bioeconomy, evolving healthcare payment models, and rapid technological innovation. At the same time, strategic investments should focus on addressing critical unmet clinical needs—particularly in areas like newly emerging infectious diseases, cancer, and chronic degenerative conditions—where current solutions remain inadequate or underdeveloped.
Project Promotion
Singleron Biotech
Newgrace Biotech Co., Ltd. is dedicated to applying groundbreaking single-cell technologies to the fields of scientific research, clinical diagnostics, health management, and drug development. The company was officially registered in January 2018 and has since raised nearly $200 million in total funding. Its core team members boast decades of expertise in areas such as genetic testing, microfluidic system development, single-cell amplification and library preparation reagent innovation, bioinformatics analysis and database construction, instrument design and engineering, as well as clinical diagnostic product development—possessing both deep-rooted technical innovation capabilities and extensive experience in successful commercialization efforts.
Lumigenex Biotech
Founded in 2010, Guangjing Biotechnology (Suzhou) Co., Ltd. is a national high-tech enterprise dedicated to the research, development, manufacturing, and sales of in vitro diagnostic products and infection-control solutions based on functional nanomaterials. The company has consistently focused on the R&D, production, distribution, and service of point-of-care testing (POCT) products within the in vitro diagnostics industry, offering customers comprehensive, intelligent solutions for rapid diagnostics and chronic disease management. Guangjing Biotechnology has attracted investments from prominent institutions such as Lenovo Star, Jin Yu Maowu, and Xiantong Capital.
ColorTech Bio
Caike (Suzhou) Biotechnology Co., Ltd. was founded in 2018 in Suzhou Industrial Park by several U.S.-returning PhDs. As a high-tech company dedicated to providing cutting-edge research tools for the life sciences, Caike has consistently focused on developing advanced technology platforms that unlock vast, high-resolution life science data—empowering applications across life science research, biopharmaceutical R&D, and clinical diagnostics. Leveraging its proprietary multi-physics biochip technology and innovative microsphere core material platform, the company has created three flagship products: Digital Cell, Single-Molecule Digital Immunoassay, and Multiplex Flow Immunofluorescence Detection. The company has attracted investments from prominent institutions including IDG, Junlian Capital, Honghui Capital, and China Investment & Innovation Fund.
ABclonal
Wuhan ABclonal Biotechnology Co., Ltd. is a global leading supplier of core antibody and molecular enzyme reagents, dedicated to providing professional and reliable products and services for diverse fields such as life science basic research, translational medicine, diagnostics, and pharmaceuticals. The company’s core business areas include research antibodies, molecular enzyme products, NGS library preparation kits, recombinant proteins with activity, diagnostic antigen-antibody raw materials, ELISA kits, and CRO services. Headquartered in Wuhan, China, ABclonal has established antibody and molecular enzyme R&D centers in Boston and Shanghai, while also building a large-scale antibody and molecular enzyme production facility in Wuhan Optics Valley Bio-city. Additionally, the company has set up direct sales teams across mainland China, the United States, Europe, Japan, Taiwan, and other regions, and has attracted investments from prominent institutions including Optics Valley Venture Capital, Jinhé Capital, Jifeng Capital, Huaxin Capital, Zhengxingu, and Sequoia Capital.
Celula
Serena (China) Medical Technology Co., Ltd. is a high-tech enterprise specializing in advanced diagnostic technologies. Founded in 2013 with its headquarters in Chengdu, it has established branches and offices in Shanghai, Zhuhai Hengqin, Beijing, and San Diego, California, USA. The company has a complete R&D, product transformation, manufacturing, and service base covering more than 5,000 square meters, supported by a multidisciplinary team of nearly 100 technical and marketing professionals. After years of technological research and development in both the United States and China, it has successfully launched the compact Sparrow flow cytometer suitable for medical institutions at all levels in China, along with supporting test kits for major diseases such as reproductive and immune disorders, and a new generation of targeted non-invasive prenatal genetic testing (NIPT) technology. The company has received investments from institutions including Jinhé Capital, Chende Capital, and Hanyi Capital.
Suzhou:+86-0512-66969722
Beijing:+86-010-65000132
Scan QR code